Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 216Irinotecan 185Cisplatin 143Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 41Cyclophosphamide 39trifluridine tipiracil drug combination 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × icaritin × Gastrointestinal × Clear all
NCT05594927 2024-08-07

BESTPOP

Beijing Shenogen Biomedical Co., Ltd

Phase 3 Recruiting
261 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03236649 2023-02-08

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Beijing Shenogen Biomedical Co., Ltd

Phase 3 Terminated
89 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01972672 2021-01-27

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

Beijing Shenogen Biomedical Co., Ltd

Phase 2 Completed
70 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡